Methods and materials for evaluating homologous recombination deficiency

The method of assessing HRD in cancer cells through chromosomal abnormalities predicts patient response to cancer treatments, addressing the lack of personalized diagnostic tools in current cancer treatment.

JP2025114740APending Publication Date: 2025-08-05MYRIAD GENETICS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2025078359
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2014-10-06
Filing Date
2025-05-09
Publication Date
2025-08-05

AI Technical Summary

Technical Problem

Current cancer treatment methods lack effective molecular diagnostic tools to characterize a patient's cancer, making it difficult to administer personalized treatment plans.

Method used

A method for assessing homologous recombination deficiency (HRD) in cancer cells by detecting specific chromosomal abnormalities such as LOH, TAI, and LST regions, and using these to predict patient response to cancer treatment regimens involving DNA damaging agents, anthracyclines, topoisomerase I inhibitors, or PARP inhibitors.

Benefits of technology

Enables personalized cancer treatment by identifying patients likely to respond to specific therapies based on HRD status, improving treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025114740000030
    Figure 2025114740000030
  • Figure 2025114740000031
    Figure 2025114740000031
  • Figure 2025114740000032
    Figure 2025114740000032
Patent Text Reader

Abstract

To provide methods and materials involved in evaluation of samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or a HRD signature.SOLUTION: Disclosed is an in vitro method for predicting patient's response to a cancer treating regimen comprising a DNA damaging agent, anthracycline, a topoisomerase I inhibitor or a PARP inhibitor, which comprises the steps of: (1) determining the number of indicator CA regions comprising at least two selected from an indicator LOH region, an indicator TAI region, and / or an indicator LST region in at least a pair of human chromosome of cancer cells of a cancer patient in a sample containing the cancer cells; and (2) diagnosing a patient whose number of the indicator LOH region, indicator TAI region or indicator LST region in the sample is larger than the reference number as having a high potential for responding to the cancer treating regimen.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Methods for predicting Anti-cancer response

    WO2012027224A1

  • Methods and materials for assessing loss of heterozygosity

    WO2013096843A1

  • Methods for predicting Anti-cancer response

    WO2013130347A1